

Robert F Dannals

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5021066/publications.pdf>

Version: 2024-02-01

116
papers

7,960
citations

76326
40
h-index

53230
85
g-index

124
all docs

124
docs citations

124
times ranked

8382
citing authors

#	ARTICLE	IF	CITATIONS
1	Neural basis of alertness and cognitive performance impairments during sleepiness. I. Effects of 24 h of sleep deprivation on waking human regional brain activity. <i>Journal of Sleep Research</i> , 2000, 9, 335-352.	3.2	914
2	Chemogenetics revealed: DREADD occupancy and activation via converted clozapine. <i>Science</i> , 2017, 357, 503-507.	12.6	813
3	Selective hypometabolism in the inferior frontal lobe in depressed patients with Parkinson's disease. <i>Annals of Neurology</i> , 1990, 28, 57-64.	5.3	400
4	Positron emission tomographic imaging of the dopamine transporter with ¹¹ C-WIN 35,428 reveals marked declines in mild Parkinson's disease. <i>Annals of Neurology</i> , 1993, 34, 423-431.	5.3	321
5	Mu-opiate receptors measured by positron emission tomography are increased in temporal lobe epilepsy. <i>Annals of Neurology</i> , 1988, 23, 231-237.	5.3	253
6	Increased mu opioid receptor binding detected by PET in cocaine-dependent men is associated with cocaine craving. <i>Nature Medicine</i> , 1996, 2, 1225-1229.	30.7	250
7	Mania after brain injury: Neuroradiological and metabolic findings. <i>Annals of Neurology</i> , 1990, 27, 652-659.	5.3	238
8	Imaging Opiate Receptors in the Human Brain by Positron Tomography. <i>Journal of Computer Assisted Tomography</i> , 1985, 9, 231-236.	0.9	237
9	PSMA-Based [18F]DCFPyL PET/CT Is Superior to Conventional Imaging for Lesion Detection in Patients with Metastatic Prostate Cancer. <i>Molecular Imaging and Biology</i> , 2016, 18, 411-419.	2.6	202
10	Column-switching HPLC for the analysis of plasma in PET imaging studies. <i>Nuclear Medicine and Biology</i> , 2000, 27, 627-630.	0.6	191
11	Quantification of mu and non-mu opiate receptors in temporal lobe epilepsy using positron emission tomography. <i>Annals of Neurology</i> , 1991, 30, 3-11.	5.3	189
12	¹⁸ F-DCFBC PET/CT for PSMA-Based Detection and Characterization of Primary Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2015, 56, 1003-1010.	5.0	180
13	Positron emission tomography imaging of serotonin transporters in the human brain using [11C](+)McN5652. <i>Synapse</i> , 1995, 20, 37-43.	1.2	161
14	In vivo detection of short- and long-term MDMA neurotoxicity? a positron emission tomography study in the living baboon brain. <i>Synapse</i> , 1998, 29, 183-192.	1.2	141
15	PET imaging of microglia by targeting macrophage colony-stimulating factor 1 receptor (CSF1R). <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 1686-1691.	7.1	140
16	Radiosynthesis of an opiate receptor binding radiotracer: [11C]carfentanil. <i>The International Journal of Applied Radiation and Isotopes</i> , 1985, 36, 303-306.	0.7	136
17	Imaging of Glial Cell Activation and White Matter Integrity in Brains of Active and Recently Retired National Football League Players. <i>JAMA Neurology</i> , 2017, 74, 67.	9.0	134
18	Comparison of Prostate-Specific Membrane Antigen-Based ¹⁸ F-DCFBC PET/CT to Conventional Imaging Modalities for Detection of Hormone-Naïve and Castration-Resistant Metastatic Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2016, 57, 46-53.	5.0	111

#	ARTICLE	IF	CITATIONS
19	Imaging of μ - and δ -opioid receptors in temporal lobe epilepsy by positron emission tomography. <i>Annals of Neurology</i> , 1997, 41, 358-367.	5.3	107
20	Peptide-Based ^{68}Ga -PET Radiotracer for Imaging PD-L1 Expression in Cancer. <i>Molecular Pharmaceutics</i> , 2018, 15, 3946-3952.	4.6	102
21	Localization of serotonin 5-HT ₂ receptors in living human brain by positron emission tomography using N1-([¹¹ C]-methyl)-2-BR-LSD. <i>Synapse</i> , 1987, 1, 393-398.	1.2	94
22	Quantification of Human Opiate Receptor Concentration and Affinity Using High and Low Specific Activity [¹¹ C]Diprenorphine and Positron Emission Tomography. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 1991, 11, 204-219.	4.3	94
23	Neural basis of alertness and cognitive performance impairments during sleepiness II. Effects of 48 and 72 h of sleep deprivation on waking human regional brain activity. <i>Thalamus & Related Systems</i> , 2003, 2, 199.	0.5	91
24	Dynamic imaging in patients with tuberculosis reveals heterogeneous drug exposures in pulmonary lesions. <i>Nature Medicine</i> , 2020, 26, 529-534.	30.7	87
25	In vivo imaging of dopamine reuptake sites in the primate brain using single photon emission computed tomography (SPECT) and iodine-123 labeled RTI-55. <i>Synapse</i> , 1992, 10, 169-172.	1.2	85
26	Cannabinoid CB ₂ Receptors in a Mouse Model of A β ² Amyloidosis: Immunohistochemical Analysis and Suitability as a PET Biomarker of Neuroinflammation. <i>PLoS ONE</i> , 2015, 10, e0129618.	2.5	83
27	Characterization of 3 Novel Tau Radiopharmaceuticals, ^{11}C -RO-963, ^{11}C -RO-643, and ^{18}F -RO-948, in Healthy Controls and in Alzheimer Subjects. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1869-1876.	5.0	81
28	Noninvasive ^{11}C -rifampin positron emission tomography reveals drug biodistribution in tuberculous meningitis. <i>Science Translational Medicine</i> , 2018, 10, .	12.4	73
29	Preclinical Evaluation of ^{18}F -RO6958948, ^{11}C -RO6931643, and ^{11}C -RO6924963 as Novel PET Radiotracers for Imaging Tau Aggregates in Alzheimer Disease. <i>Journal of Nuclear Medicine</i> , 2018, 59, 675-681.	5.0	71
30	[¹²³ I/ ¹²⁵ I]RTI-55, an in vivo label for the serotonin transporter. <i>Synapse</i> , 1992, 11, 134-139.	1.2	70
31	Imaging of μ opioid receptors in human brain by N1 μ - ([¹¹ C]methyl)naltrindole and PET. , 1996, 24, 19-28.		69
32	Synthesis of a radiotracer for studying nicotinic acetylcholine receptors: (+/ α ⁺)-exo-2-(2-[¹⁸ F]fluoro-5-pyridyl)-7-azabicyclo[2.2.1]heptane. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 1996, 38, 355-365.	1.0	67
33	Imaging Muscarinic Cholinergic Receptors in Human Brain in vivo with SPECT, [¹²³ I]4-Iododexetimide, and [¹²³ I]4-Iodoletetimide. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 1992, 12, 562-570.	4.3	60
34	An improved synthesis of the radiolabeled prostate-specific membrane antigen inhibitor, [^{18}F]DCFPyL. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2016, 59, 439-450.	1.0	59
35	[¹²⁵ I/ ¹²³ I]IPH: A radioiodinated analog of epibatidine for in vivo studies of nicotinic acetylcholine receptors. , 1997, 26, 392-399.		52
36	Radiosynthesis of 3-[¹⁸ F]fluoropropyl and 4-[¹⁸ F]fluorobenzyl triarylphosphonium ions. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2004, 47, 469-476.	1.0	52

#	ARTICLE	IF	CITATIONS
37	Doses of GBR12909 that suppress cocaine self-administration in non-human primates substantially occupy dopamine transporters as measured by [¹¹ C] WIN35,428 PET scans. , 1999, 32, 44-50.		50
38	GBR12909 attenuates amphetamine-induced striatal dopamine release as measured by [¹¹ C]raclopride continuous infusion PET scans. Synapse, 1999, 33, 268-273.	1.2	50
39	Imaging <i>Enterobacteriales</i> infections in patients using pathogen-specific positron emission tomography. Science Translational Medicine, 2021, 13, .	12.4	49
40	Cerebral Glucose Utilization in Polysubstance Abuse. Neuropsychopharmacology, 1995, 13, 21-31.	5.4	48
41	Determination of [¹¹ C]Rifampin Pharmacokinetics within Mycobacterium tuberculosis-Infected Mice by Using Dynamic Positron Emission Tomography Bioimaging. Antimicrobial Agents and Chemotherapy, 2015, 59, 5768-5774.	3.2	47
42	Development of a High-Affinity PET Radioligand for Imaging Cannabinoid Subtype 2 Receptor. Journal of Medicinal Chemistry, 2016, 59, 7840-7855.	6.4	47
43	Imaging glial activation in patients with post-treatment Lyme disease symptoms: a pilot study using [¹¹ C]DPA-713 PET. Journal of Neuroinflammation, 2018, 15, 346.	7.2	46
44	Cerebral Glucose Utilization Is Reduced in Second Test Session. Journal of Cerebral Blood Flow and Metabolism, 1997, 17, 704-712.	4.3	43
45	Nicotine induced up-regulation of nicotinic receptors in CD-1 mice demonstrated with an in vivo radiotracer: Gender differences. Synapse, 1998, 30, 116-118.	1.2	40
46	Synthesis of carbon-11 labeled diprenorphine: A radioligand for positron emission tomographic studies of opiate receptors. Tetrahedron Letters, 1987, 28, 4015-4018.	1.4	38
47	In vivo studies of opiate receptors. Annals of Neurology, 1984, 15, 85-92.	5.3	37
48	Multiparametric Molecular Imaging Provides Mechanistic Insights into Sympathetic Innervation Impairment in the Viable Infarct Border Zone. Journal of Nuclear Medicine, 2015, 56, 457-463.	5.0	37
49	Use of Positron Emission Tomography to Study AT1 Receptor Regulation In Vivo. Journal of the American Society of Nephrology: JASN, 2001, 12, 1350-1358.	6.1	37
50	Decreased hippocampal muscarinic cholinergic receptor binding measured by ¹²³ I-iododexetimide and single-photon emission computed tomography in epilepsy. Annals of Neurology, 1993, 34, 235-238.	5.3	35
51	[¹¹ C]-GR89696, a potent kappa opiate receptor radioligand; in vivo binding of the R and S enantiomers. Nuclear Medicine and Biology, 2002, 29, 47-53.	0.6	34
52	Development of imaging agents for the dopamine transporter. Medicinal Research Reviews, 1995, 15, 419-444.	10.5	33
53	Synthesis of 1-(2,4-dichlorophenyl)-4-cyano-5-(4-[¹¹ C]methoxyphenyl)-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide ([¹¹ C]JHU75528) and 1-(2-bromophenyl)-4-cyano-5-(4-[¹¹ C]methoxyphenyl)-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide ([¹¹ C]JHU75575) as potential radioligands for PET imaging of cerebral cannabinoid receptor. Journal of Labelled Compounds and Radiopharmaceuticals, 2006, 49, 1021-1036.	1.0	32
54	[¹¹ C]-methyl 4-[(3,4-dichlorophenyl)acetyl]-3-[(1-pyrrolidinyl)methyl]-1-piperazinecarboxylate ([¹¹ C]GR89696): synthesis and in vivo binding to kappa opiate receptors. Nuclear Medicine and Biology, 1999, 26, 737-741.	0.6	28

#	ARTICLE	IF	CITATIONS
55	¹¹ C-MCG: Synthesis, Uptake Selectivity, and Primate PET of a Probe for Glutamate Carboxypeptidase II (NAALADase). Molecular Imaging, 2002, 1, 153535002002021.	1.4	27
56	The distribution of the $\alpha 7$ nicotinic acetylcholine receptor in healthy aging: An in vivo positron emission tomography study with [¹⁸ F]ASEM. NeuroImage, 2018, 165, 118-124.	4.2	27
57	Characterization of [¹¹ C]RO5013853, a novel PET tracer for the glycine transporter type 1 (GlyT1) in humans. NeuroImage, 2013, 75, 282-290.	4.2	26
58	Buprenorphine Reduces Cerebral Glucose Metabolism in Polydrug Abusers. Neuropsychopharmacology, 1994, 10, 157-170.	5.4	25
59	Neuroimaging of translocator protein in patients with systemic lupus erythematosus: a pilot study using [¹¹ C]DPA-713 positron emission tomography. Lupus, 2017, 26, 170-178.	1.6	25
60	Feasibility Evaluation of Myocardial Cannabinoid Type 1 Receptor Imaging in Obesity. JACC: Cardiovascular Imaging, 2018, 11, 320-332.	5.3	24
61	Mechanistic Insights into Sympathetic Neuronal Regeneration. Circulation: Cardiovascular Imaging, 2015, 8, e003507.	2.6	23
62	Synthesis and quality control of [¹⁸ F]T807 for tau PET imaging. Journal of Labelled Compounds and Radiopharmaceuticals, 2016, 59, 411-415.	1.0	23
63	Synthesis of a mGluR5 antagonist using [¹¹ C]copper(I) cyanide. Journal of Labelled Compounds and Radiopharmaceuticals, 2006, 49, 829-834.	1.0	22
64	High Availability of the $\alpha 7$ -Nicotinic Acetylcholine Receptor in Brains of Individuals with Mild Cognitive Impairment: A Pilot Study Using ¹⁸ F-ASEM PET. Journal of Nuclear Medicine, 2020, 61, 423-426.	5.0	22
65	Synthesis of N ¹ -([¹¹ C]methyl)naltrexone ([¹¹ C]MeNTI): A radioligand for positron emission tomographic studies of delta opioid receptors. Journal of Labelled Compounds and Radiopharmaceuticals, 1995, 36, 137-145.	1.0	21
66	Synthesis of a radioiodinated analog of epibatidine: (\pm)-exo-2-(2-iodo-5-pyridyl)-7-azabicyclo[2.2.1]heptane for in vitro and in vivo studies of nicotinic acetylcholine receptors. Journal of Labelled Compounds and Radiopharmaceuticals, 1997, 39, 39-48.	1.0	21
67	Dose-dependent, saturable occupancy of the metabotropic glutamate subtype 5 receptor by fenobam as measured with [¹¹ C]ABP688 PET imaging. Synapse, 2014, 68, 565-573.	1.2	21
68	Facile synthesis of [¹¹ C]buprenorphine for positron emission tomographic studies of opioid receptors. International Journal of Radiation Applications and Instrumentation Part A, Applied Radiation and Isotopes, 1990, 41, 745-752.	0.5	19
69	Synthesis of [¹¹ C]gefitinib for imaging epidermal growth factor receptor tyrosine kinase with positron emission tomography. Journal of Labelled Compounds and Radiopharmaceuticals, 2006, 49, 883-888.	1.0	19
70	¹⁸ F-FNDP for PET Imaging of Soluble Epoxide Hydrolase. Journal of Nuclear Medicine, 2016, 57, 1817-1822.	5.0	19
71	Positron emission tomography radioligands for the opioid system. Journal of Labelled Compounds and Radiopharmaceuticals, 2013, 56, 187-195.	1.0	18
72	PET-measured longitudinal flow gradient correlates with invasive fractional flow reserve in CAD patients. European Heart Journal Cardiovascular Imaging, 2016, 18, jew116.	1.2	18

#	ARTICLE	IF	CITATIONS
73	Noncompartmental and compartmental modeling of the kinetics of carbon-11 labeled pyrilamine in the human brain. <i>Synapse</i> , 1993, 15, 263-275.	1.2	17
74	Radiosynthesis of [¹¹ C]paclitaxel. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2002, 45, 471-477.	1.0	17
75	Dissociative Changes in the B _{max} and K _D of Dopamine D ₂ /D ₃ Receptors with Aging Observed in Functional Subdivisions of the Striatum: A Revisit with an Improved Data Analysis Method. <i>Journal of Nuclear Medicine</i> , 2012, 53, 805-812.	5.0	17
76	Synthesis of [¹⁸ F] SR144385: a selective radioligand for positron emission tomographic studies of brain cannabinoid receptors. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 1999, 42, 589-596.	1.0	16
77	Synthesis and initial in vitro characterization of 6-[¹⁸ F]fluoro-3-(2(S)-azetidylmethoxy)pyridine, a high-affinity radioligand for central nicotinic acetylcholine receptors. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2000, 43, 413-423.	1.0	16
78	Pre-clinical characterization of [¹¹ C]R05013853 as a novel radiotracer for imaging of the glycine transporter type 1 by positron emission tomography. <i>NeuroImage</i> , 2013, 75, 291-300.	4.2	16
79	Dynamic PET-facilitated modeling and high-dose rifampin regimens for <i>Staphylococcus aureus</i> orthopedic implant-associated infections. <i>Science Translational Medicine</i> , 2021, 13, eabl6851.	12.4	16
80	¹⁸ F-XTRA PET for Enhanced Imaging of the Extrathalamic $\alpha 4\beta 2$ Nicotinic Acetylcholine Receptor. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1603-1608.	5.0	15
81	Osteopontin/secreted phosphoprotein-1 behaves as a molecular brake regulating the neuroinflammatory response to chronic viral infection. <i>Journal of Neuroinflammation</i> , 2020, 17, 273.	7.2	14
82	Synthesis of a Radiotracer for Studying κ -Subtype Opiate Receptors: N-[¹¹ C-methyl]-N-(trans-2-pyrrolidinyl-cyclohexyl)-3,4-dichlorophenylacetamide ([¹¹ C](\pm)-U-50488H). <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 1992, 31, 81-89.	1.0	12
83	P4485: First in-human PET study of 3 novel tau radiopharmaceuticals: [¹¹ C]RO6924963, [¹¹ C]RO6931643, and [¹⁸ F]RO6958948. <i>Alzheimer's and Dementia</i> , 2015, 11, P850.	0.8	12
84	Effect of STN DBS on vesicular monoamine transporter 2 and glucose metabolism in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2019, 64, 235-241.	2.2	12
85	Brown Adipose Tissue Response Dynamics: In Vivo Insights with the Voltage Sensor 18F-Fluorobenzyl Triphenyl Phosphonium. <i>PLoS ONE</i> , 2015, 10, e0129627.	2.5	12
86	Effects of Vasopressin on Blood-Brain Transfer of Methionine in Dogs. <i>Journal of Neurochemistry</i> , 1992, 59, 1421-1429.	3.9	11
87	Synthesis of N1-([¹⁸ F]fluoroethyl)naltrindole ([¹⁸ F]FETNTI): a radioligand for positron emission tomographic studies of delta opioid receptors. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 1999, 42, 43-54.	1.0	11
88	Imaging $\alpha 4\beta 2$ Nicotinic Acetylcholine Receptors (nAChRs) in Baboons with [¹⁸ F]XTRA, a Radioligand with Improved Specific Binding in Extra-Thalamic Regions. <i>Molecular Imaging and Biology</i> , 2017, 19, 280-288.	2.6	11
89	¹¹ C-PABA as a PET Radiotracer for Functional Renal Imaging: Preclinical and First-in-Human Study. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1665-1671.	5.0	11
90	¹¹ C-Para-aminobenzoic acid PET imaging of <i>S. aureus</i> and MRSA infection in preclinical models and humans. <i>JCI Insight</i> , 2022, 7, .	5.0	11

#	ARTICLE	IF	CITATIONS
91	Synthesis of 3-[(1-[¹¹ C]methyl-2(S)-pyrrolidinyl) methoxy]pyridine and 3-[(1-[¹¹ C]methyl-2(R)-pyrrolidinyl) methoxy]pyridine: Radioligands for in vivo studies of neuronal nicotinic acetylcholine receptors. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 1997, 39, 425-431.	1.0	10
92	Radiosynthesis and validation of [⁵ â€cyanoâ€i>N</i>â€{4â€{4â€{ ¹¹ </sup>C}methylpiperazinâ€1â€yl)â€2â€(piperidinâ€1â€yl)phenyl} furanâ€2â€carboxamide] ([¹¹ </sup>C]CPPC), a PET radiotracer for imaging CSF1R, a microgliaâ€specific marker. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2019, 62, 903-908.	1.0	10
93	Molecular imaging of the serotonin transporter availability and occupancy by antidepressant treatment in late-life depression. <i>Neuropharmacology</i> , 2021, 194, 108447.	4.1	10
94	Cerebral Glucose Utilization in Polysubstance Abuse. <i>Neuropsychopharmacology</i> , 1995, 13, 21-31.	5.4	10
95	PET imaging of soluble epoxide hydrolase in non-human primate brain with [¹⁸ F]FNDP. <i>EJNMMI Research</i> , 2020, 10, 67.	2.5	10
96	Effect of tracer metabolism on PET measurement of [¹¹ C]pyrilamine binding to histamine H1 receptors. <i>Annals of Nuclear Medicine</i> , 1999, 13, 101-107.	2.2	9
97	Synthesis of carbon-11 labeled methylcarbamates from [¹¹ C]-methylchloroformate. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 1995, 36, 365-371.	1.0	8
98	[¹²⁵ I]Iodo-ASEM, a specific in vivo radioligand for Î±7-nAChR. <i>Nuclear Medicine and Biology</i> , 2015, 42, 488-493.	0.6	8
99	Development of a radioligand for imaging V1a vasopressin receptors with PET. <i>European Journal of Medicinal Chemistry</i> , 2017, 139, 644-656.	5.5	8
100	An optimized radiosynthesis of [¹⁸ F]FNDP, a positron emission tomography radiotracer for imaging soluble epoxide hydrolase (sEH). <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2018, 61, 567-572.	1.0	8
101	The Relationship of Varenicline Agonism of Î±4Î²2 Nicotinic Acetylcholine Receptors and Nicotine-Induced Dopamine Release in Nicotine-Dependent Humans. <i>Nicotine and Tobacco Research</i> , 2020, 22, 892-899.	2.6	8
102	Synthesis and Evaluation of a New ¹⁸ F-Labeled Radiotracer for Studying the GABAB Receptor in the Mouse Brain. <i>ACS Chemical Neuroscience</i> , 2018, 9, 1453-1461.	3.5	7
103	¹⁸ F-labeled radiotracers for in vivo imaging of DREADD with positron emission tomography. <i>European Journal of Medicinal Chemistry</i> , 2021, 213, 113047.	5.5	7
104	In vivo studies of [¹²⁵ I]iodobenzamide and [¹¹ C]iodobenzamide: A ligand suitable for positron emission tomography and single photon emission tomography imaging of cerebral D2 dopamine receptors. <i>Synapse</i> , 1992, 12, 236-241.	1.2	6
105	Radiosynthesis and validation of [¹¹ </sup>C]4â€A</sc>minobenzoic acid ([¹¹ </sup>C]PABA), a PET radiotracer for imaging bacterial infections. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2019, 62, 28-33.	1.0	6
106	First-in-human neuroimaging of soluble epoxide hydrolase using [¹⁸ F]FNDP PET. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 3122-3128.	6.4	6
107	Radiosynthesis of [⁵ â€{ ¹¹ </sup>C}methanesulfonylâ€2â€{(<i>S</i>)â€2,2â€trifluoroâ€1â€methylâ€ethoxy}â€phenyl]â€5â€{tetrahydroâ€pyran-2-yl}carboxamide ([¹¹ </sup>C]RO5013853), a novel PET tracer for the glycine transporter type I (GlyT1). <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2011, 54, 702-707.	1.0	5
108	Regional amyloid correlates of cognitive performance in ageing and mild cognitive impairment. <i>Brain Communications</i> , 2022, 4, fcac016.	3.3	5

#	ARTICLE	IF	CITATIONS
109	External monitoring of cerebral nicotinic acetylcholine receptors in living mice. <i>Synapse</i> , 1997, 27, 378-380.	1.2	4
110	A side-by-side evaluation of [18F]FDOPA enantiomers for non-invasive detection of neuroendocrine tumors by positron emission tomography. <i>Oncotarget</i> , 2019, 10, 5731-5744.	1.8	3
111	Assessing neuroreceptor occupancy by continuous infusion of carbon-11 labeled radioligands. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1996, 23, 141-144.	2.1	2
112	Synthesis of 3-[(1-[11C]methyl-2(S)-pyrrolidinyl) methoxy]pyridine and 3-[(1-[11C]methyl-2(R)-pyrrolidinyl) methoxy]pyridine: Radioligands for in vivo studies of neuronal nicotinic acetylcholine receptors. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 1997, 39, 425-431.	1.0	2
113	Characterization of dose dependent norepinephrine transporter blockade by atomoxetine in human brain using 11C MeNER PET. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2005, 25, S599-S599.	4.3	2
114	PET/CT imaging of CSF1R in a mouse model of tuberculosis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 4088-4096.	6.4	1
115	Radiosynthesis of the $\alpha 4 \beta 2$ nicotinic acetylcholine receptor ligand: 5-((1-[11C]-methyl-2-(S)-pyrrolidinyl)methoxy)-2-chloro-3-((E)-2-(2-fluoropyridin-4-yl)vinyl)pyridine. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2006, 49, 459-462.	1.0	0
116	Bengt Långström - personal recollections of the gentle giant of short-lived radiotracers. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2015, 58, 49-50.	1.0	0